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COMMENTARY Open Access
FAK-inhibition opens the door to
checkpoint immunotherapy in
Pancreatic Cancer
Stefan N. Symeonides2, Stephen M. Anderton1 and Alan Serrels1,2*
Abstract
Immunotherapy has had remarkable success in the treatment of some cancer types. However, pancreatic cancer
has remained largely refractory to immunotherapy, including immune checkpoint inhibitors. Recently, Jiang and
colleagues identified a key role for FAK in regulating the composition of the fibrotic and immuno-suppressive
pancreatic tumour niche, and showed that FAK inhibitors can be used in combination with immune checkpoint
blockade and gemcitabine chemotherapy to significantly delay pancreatic tumour progression. This study further
supports the use of FAK inhibitors in combination with immunotherapy.
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Main Text
Despite our increased understanding of the pathology of
pancreatic cancer, prognosis remains sadly limited. In the
United Kingdom, 1-year survival for pancreatic adenocar-
cinoma presentations is just 21% and 5-year survival just
3% (Cancer Research UK) “(http://www.cancerresearchu
k.org/health-professional/cancer-statistics/statistics-by-canc
er-type/pancreatic-cancer)”. As a result, pancreatic cancer
is the 4th to 5th most common cause of cancer death in
the UK & US, and is predicted to be the second common-
est cause by 2020. Improvements in combination chemo-
therapy for the fittest patients has come at the cost of
significant toxicity, while novel agents have not yet made
an impact. Harnessing the body’s own immune system to
kill cancer cells has shown promise for a growing number
of cancer types, most notably changing the treatment land-
scape of melanoma [1]. However, pancreatic cancer has
remained largely refractory to immunotherapy, including
immune checkpoint inhibitors [2]. In a recent issue of the
journal Nature Medicine, Jiang and colleagues identify that
inhibition of the non-receptor tyrosine kinase, Focal Adhe-
sion Kinase (FAK), can sensitise genetically engineered
mouse (GEM) models of pancreatic cancer to the anti-
tumour effects of immune checkpoint blockade [3]. They
show that this synergistic activity is underpinned by repro-
gramming of the fibrotic and immuno-suppressive pancre-
atic tumour microenvironment (TME) in response to
treatment with a small molecule FAK kinase inhibitor, and
that this is at least in part mediated through FAK-
dependent regulation of chemokine expression. This work
elegantly illustrates the potential for FAK kinase inhibitors
to work alongside immunotherapy.
FAK reprograms the immuno-suppressive pancreatic
tumour niche
FAK is frequently upregulated in many cancer types, and
signals downstream of integrins and growth factor re-
ceptors to control a variety of cellular functions that are
important for the malignant phenotype, including adhe-
sion, migration, invasion, proliferation, and survival [4].
Recently, we identified an unexpected role for FAK in
regulating the anti-tumour immune response in a mouse
model of skin squamous cell carcinoma (SCC) [5]. We
found that FAK-dependent regulation of chemokines
and cytokines in cancer cells was required to drive ele-
vated levels of regulatory T-cells (Tregs) into the tumour
environment, resulting in suppression of the anti-
tumour CD8+ T-cell response. This was mediated
through nuclear FAK signalling in cancer cells, and
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treatment with a small molecule FAK kinase inhibitor
resulted in immune-mediated tumour regression. Thus,
targeting FAK could unlock the anti-tumour immune re-
sponse through regulating the immuno-suppressive
tumour environment. Jiang and colleagues investigated
the immuno-modulatory effects of FAK kinase inhibition
in GEM models of pancreatic cancer, and explored the
potential for combination with immune checkpoint
blockade [3]. They identified that FAK signalling in can-
cer cells acts to broadly regulate the composition of the
TME. They report a reduction in the number of tumour
infiltrating (1) FAP+ fibroblasts, (2) myeloid derived sup-
pressor cells (MDSC), (3) CD206+ macrophages, and (4)
Tregs (Fig. 1). In some instances, this was also accom-
panied by elevated CD8+ T-cell infiltration into FAK-
depleted tumours. In addition, the authors also identified
that FAK inhibition reduces collagen deposition within
the tumour environment, overcoming a physical barrier
to T-cell infiltration. These changes collectively repro-
gram the pancreatic TME, shifting the balance in favour
of anti-tumour immunity. In seeking to explore the
mechanism underpinning this, the authors identified
that FAK regulates the expression/secretion of a number
of chemokines in pancreatic cancer cells, consistent with
previous reports using other cell types [5, 6]. In particu-
lar, they focused on CXCL12, demonstrating that it may
play an important role in stromal expansion within the
pancreatic tumour niche through driving increased pro-
liferation of pancreatic fibroblasts. This observation is
consistent with previous reports identifying a reduction
in fibroblast infiltration into pancreatic tumours follow-
ing treatment with a FAK inhibitor [7], and builds on
our previous finding that FAK-dependent expression of
the chemokine CCL5 in cancer cells was required to
drive elevated levels of Tregs into SCC tumours [5].
Together, these findings identify that FAK-regulated
chemokine expression is an important mechanism
through which cancer cells exert influence over the
composition of the surrounding TME in order to evade
the anti-tumour immune response. Further work will be
required to fully understand the mechanisms of FAK-
dependent chemokine regulation, and its contribution to
regulation of the TME in cancer.
FAK inhibition synergises with immune checkpoint
blockade to improve survival time
In seeking to explore the therapeutic value of FAK-
dependent changes in the immuno-suppressive tumour
environment, Jiang and colleagues made excellent use of
the KPC and KPPC GEM models of pancreatic cancer.
These tumours did not respond to the combination of
anti-CTLA-4 and anti-PD-1, reflecting the outcomes of
clinical trials [2]. However, combination with VS-4718
[8], one of a number of FAK kinase inhibitors in clinical
development [9], and gemcitabine, one of the standard
of care chemotherapies for pancreatic cancer, led to a
synergistic and significant anti-tumour response and
even long-term survival of a small number of mice from
the cohort receiving this treatment (Fig. 1). These results
are extremely encouraging and further support the ra-
tionale for FAK/immunotherapy combinations to be
tested in the clinic. Furthermore, they provide additional
evidence that immunotherapy may yet work in pancre-
atic cancer, if the right combination of agents can be
found. However, clinical translation of this 4-way com-
bination may require to be staged in order to fully
understand the contribution of each agent and the
potential toxicity each will add. For example, it is already
Fig. 1 FAK inhibition reprograms the immuno-suppressive environment in pancreatic tumors rendering them sensitive to immune checkpoint
blockade. (1) Pancreatic Ductal Adenocarcinoma contains a highly fibrotic and immuno-suppressive microenvironment. (2) Inhibition of FAK
kinase activity results in extensive remodeling of the fibrotic and immuno-suppressive tumor niche that results in a modest improvement in
survival time. (3) Combining the effects of FAK inhibition with checkpoint blockade and gemcitabine chemotherapy results in a significant
improvement in survival time and even long-term survival
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established that the combination of anti-CTLA-4 and
anti-PD-1 can result in potentially severe immune-
mediated side-effects that require careful clinical
management [1], prompting exploration of de-escalated
dosing and/or scheduling. Clinical trials combining anti-
PD-1 with gemcitabine are already underway, and
similar trials incorporating FAK inhibitors have either
started or are due to start soon. This is the first time
FAK inhibitors have been tested in combination with im-
munotherapy and the preclinical data are very encour-
aging. However, we do not yet know if this is the
optimal combination. Future studies will need to address
this in detail, both in terms of efficacy and tolerability,
for translation to the clinic.
Clinical impact
The work reported by Jiang and colleagues has seen rapid
clinical translation, and has resulted in a clinical trial to test
the safety, tolerability, and anti-tumour efficacy of the FAK
inhibitor defactinib in combination with pembrolizumab
(anti-PD-1) and gemcitabine in advanced pancreatic cancer
(clinicalTrials.gov NCT02546531). This will run alongside
a further clinical trial that stemmed from our work, which
will aim to assess the safety, tolerability, and anti-tumour
efficacy of defactinib in combination with pembrolizumab
in pancreatic cancer, non-small cell lung cancer, and meso-
thelioma (clinicalTrials.gov NCT02758587). With clinical
testing now underway, we look forward to determining
whether the highly encouraging pre-clinical data will trans-
late into clinical benefit in treating these cancers of high
unmet need. A key aspect of this ongoing work is the loop
back to the laboratory, exploring those real-life biological
effects, thereby refining and optimising future combination
immunotherapy.
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